Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
Gastrointestinal Cancers

Jean-Luc Van Laethem, ESMO 2021: Updated Results of the Phase II KEYNOTE-224 Study

Copy Link
Published Online: Oct 5th 2021

touchONCOLOGY joins Professor Jean-Luc Van Laethem (Erasme University Hospital, Brussels, Belgium), principle investigator of the KEYNOTE-224 study, to discuss the updated results for pembrolizumab monotherapy as first-line therapy for advanced hepatocellular carcinoma.

Questions
1. What were the objectives of the KEYNOTE-224 study? (00:38-01:33)
2. What have previous study findings taught us about the clinical utility of pembrolizumab monotherapy as therapy for advanced hepatocellular carcinoma (HCC)? (01:33-02:52)
3. Could you give us an overview of the latest results from the KEYNOTE-244 study? (02:52-04:00)
4. Where do you place pembrolizumab in future treatment paradigms for HCC? (04:00-05:12)
5. How can outcomes with pembrolizumab in this indication be further improved and what future studies are planned? (05:12-06:03)

Disclosures: Jean-Luc Van Laethem has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ESMO 2021 Annual Meeting.

Share this Video
Related Videos In Gastrointestinal Cancers
Gastrointestinal Cancers, Pancreatic Cancer
Developed by Touch
Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer
Watch Time: 8 mins

Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]

Gastrointestinal Cancers, Pancreatic Cancer
Developed by Touch
Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer
Watch Time: 1 min

Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]

Gastrointestinal Cancers
Developed by Touch
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
Watch Time: 4 mins

The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]

Trending In Gastrointestinal Cancers:

Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer
Gastrointestinal Cancers, Pancreatic Cancer
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72